Welcome to our dedicated page for Embecta SEC filings (Ticker: EMBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading 250 pages of medical-device jargon to find out how a 300-unit insulin patch pump affects margins? Embecta’s SEC filings can feel as technical as its pen needles. From intricate FDA disclosures to segment-level cost data, locating what truly moves EMBC’s share price is a challenge.
Stock Titan solves that problem. Our AI turns every Embecta quarterly earnings report 10-Q filing, Embecta annual report 10-K simplified, and Embecta 8-K material events explained into clear language you can skim in minutes. Need to monitor Embecta insider trading Form 4 transactions? We stream Embecta Form 4 insider transactions real-time, flagging executive buys and sells the moment they hit EDGAR. Want the numbers behind the new patch-pump production line? Our platform highlights R&D spend, manufacturing gross margin shifts, and litigation risks—no manual page-flip required.
Here’s what you’ll unlock:
- AI-powered summaries that spotlight pump-technology milestones and contract-manufacturing revenue
- Instant alerts on Embecta executive stock transactions Form 4 and upcoming Embecta proxy statement executive compensation details
- Side-by-side charts for Embecta earnings report filing analysis—track insulin-delivery segment trends quarter over quarter
Embecta Corp. (EMBC) Q3 FY2025 highlights: For the three months ended June 30, 2025 revenues were $295.5 million versus $272.5 million a year earlier and net income was $45.5 million versus $14.7 million. Diluted EPS was $0.78 versus $0.25. For the nine months ended June 30, 2025 revenues were $816.4 million versus $837.0 million and net income was $69.0 million versus $63.7 million.
Key operating and balance sheet items: Gross profit for the quarter was $197.1 million; operating income was $94.0 million. Cash and equivalents were $230.6 million at June 30, 2025. Long-term debt (net of discounts and issuance costs) was $1,458.8 million and total principal outstanding was $1,489.1 million. Total assets were $1,157.3 million and total equity was negative $669.6 million.
- Restructuring: Patch Pump charges totaled $34.3 million and a 2025 restructuring plan added $3.5 million during the nine months.
- Cash flow: Net cash provided by operating activities was $107.7 million for the nine months.
- Receivables: $26.2 million of receivables were sold during the period.
FAQ
What is the current stock price of Embecta (EMBC)?
What is the market cap of Embecta (EMBC)?
